Hyundai ADM Bio said on the 3rd that it will begin a phase 1 clinical trial combining an immuno-oncology drug for patients with terminal breast and lung cancer.
This is the first in-house led clinical trial since the company was founded. Through this trial, the company plans to verify whether the core pipeline "Penitrium" suppresses cancer cell metastasis and enhances the therapeutic effect of existing immuno-oncology drugs.
Penitrium was developed based on a mechanism that softens the rigid extracellular matrix (ECM) around tumor tissue to ease the structural barriers of the tumor microenvironment and help existing anticancer drugs penetrate more effectively into the tumor tissue.
Cho Won-dong, CEO of Hyundai ADM Bio, said, "If the parent company Hyundai Bioscience is focused on easing pain in the course of treatment through a prostate cancer trial, Hyundai ADM Bio aims to block cancer metastasis and overcome the factors that directly threaten patients' survival."